Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

16.00
-5.5500-25.75%
Pre-market: 16.420.4200+2.63%08:16 EDT
Volume:13.97M
Turnover:226.06M
Market Cap:1.26B
PE:-8.86
High:18.62
Open:13.54
Low:12.99
Close:21.55
52wk High:36.26
52wk Low:2.86
Shares:78.66M
Float Shares:53.14M
Volume Ratio:11.44
T/O Rate:26.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8064
EPS(LYR):-2.2041
ROE:-59.22%
ROA:-34.41%
PB:4.09
PE(LYR):-7.26

Loading ...

Stock Track | Olema Pharmaceuticals Skyrockets 208.80% Pre-Market on JPMorgan's Bullish Price Target Hike

Stock Track
·
Nov 18, 2025

Olema Oncology price target raised to $32 from $29 at JPMorgan

TIPRANKS
·
Nov 18, 2025

Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Nov 11, 2025

Promising Developments and Strategic Collaborations Boost Olema Pharmaceuticals’ Buy Rating

TIPRANKS
·
Nov 11, 2025

Optimistic Buy Rating for Olema Pharmaceuticals Driven by Unique Phase III Trials and Promising Market Potential

TIPRANKS
·
Nov 11, 2025

Olema Pharmaceuticals Q3 EPS $(0.49) Misses $(0.45) Estimate

Benzinga
·
Nov 10, 2025

Olema Pharmaceuticals posts Q3 net loss of $42.2 million on higher R&D spending

Reuters
·
Nov 10, 2025

BRIEF-Olema Pharmaceuticals Q3 Net Income USD -42.217 Million

Reuters
·
Nov 10, 2025

Olema Pharmaceuticals Q3 Income From Operations USD -45.877 Million

THOMSON REUTERS
·
Nov 10, 2025

Press Release: Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Dow Jones
·
Nov 10, 2025

Olema Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 05, 2025

Olema Pharmaceuticals Inc. to Participate in Jefferies London Healthcare Conference

Reuters
·
Nov 04, 2025

Olema Pharmaceuticals Announces Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib for Advanced Breast Cancer

Reuters
·
Oct 31, 2025

Promising Outlook for Olema Pharmaceuticals: Buy Rating Driven by Palazestrant’s Potential in Breast Cancer Treatment

TIPRANKS
·
Oct 27, 2025

JPMorgan healthcare analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 23, 2025

Olema Pharmaceuticals Reports Positive Phase 1b/2 Trial Results

TIPRANKS
·
Oct 21, 2025

Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector

MT Newswires Live
·
Oct 20, 2025

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga
·
Oct 20, 2025

Olema Pharmaceuticals Price Target Maintained With a $28.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20, 2025